Integrating in vitro and in silico approaches to evaluate the “dual functionality” of palmatine chloride in inhibiting and disassembling Tau-derived VQIVYK peptide fibrils

Alzheimer's disease (AD) is the most common neurodegenerative disorder which is characterized by the deposits of intra-cellular tau protein and extra-cellular amyloid-β (Aβ) peptides in the human brain. Understanding the mechanism of protein aggregation and finding compounds that are capable of...

Full description

Saved in:
Bibliographic Details
Published in:Biochimica et biophysica acta. General subjects 2018-07, Vol.1862 (7), p.1565-1575
Main Authors: Haj, Esraa, Losev, Yelena, Guru KrishnaKumar, V., Pichinuk, Edward, Engel, Hamutal, Raveh, Avi, Gazit, Ehud, Segal, Daniel
Format: Article
Language:English
Subjects:
Adrenal Gland Neoplasms - pathology
Aggregation modulator
Amyloid
Amyloid - drug effects
Amyloid - ultrastructure
Berberine Alkaloids - pharmacology
Circular Dichroism
Computer Simulation
High-Throughput Screening
High-Throughput Screening Assays
Humans
In Vitro Techniques
Molecular Docking Simulation
Palmatine
Peptide Fragments - chemistry
Peptide Fragments - drug effects
Pheochromocytoma - pathology
PHF6 peptide
Protein Aggregation, Pathological
Tau protein
tau Proteins - chemistry
tau Proteins - drug effects
Tumor Cells, Cultured
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer's disease (AD) is the most common neurodegenerative disorder which is characterized by the deposits of intra-cellular tau protein and extra-cellular amyloid-β (Aβ) peptides in the human brain. Understanding the mechanism of protein aggregation and finding compounds that are capable of inhibiting its aggregation is considered to be highly important for disease therapy. We used an in vitro High-Throughput Screening for the identification of potent inhibitors of tau aggregation using a proxy model; a highly aggregation-prone hexapeptide fragment 306VQIVYK311 derived from tau. Using ThS fluorescence assay we screened a library of 2401 FDA approved, bio-active and natural compounds in attempt to find molecules which can efficiently modulate tau aggregation. Among the screened compounds, palmatine chloride (PC) alkaloid was able to dramatically reduce the aggregation propensity of PHF6 at sub-molar concentrations. PC was also able to disassemble preformed aggregates of PHF6 and reduce the amyloid content in a dose-dependent manner. Insights obtained from MD simulation showed that PC interacted with the key residues of PHF6 responsible for β-sheet formation, which could likely be the mechanism of inhibition and disassembly. Furthermore, PC could effectively inhibit the aggregation of full-length tau and disassemble preformed aggregates. We found that PC possesses “dual functionality” towards PHF6 and full-length tau, i.e. inhibit their aggregation and disassemble pre-formed fibrils. The “dual functionality” of PC is valuable as a disease modifying strategy for AD, and other tauopathies, by inhibiting their progress and reducing the effect of fibrils already present in the brain. [Display omitted] •Using HTS, 2401 small molecule compounds were tested for their ability to modulate aggregation of tau-derived PHF6 peptide.•Palmatine chloride exhibited the highest inhibitory effect as determined by ThS assay, CD spectroscopy and TEM analysis.•Palmatine chloride was also able to effectively disassemble pre-formed β-sheet rich PHF6 fibrils.•MD studies revealed that palmatine interacts with Val of PHF6 a key residue responsible for maintaining β-sheets in fibrils.•Palmatine chloride effectively inhibited aggregation of the full-length tau and disassembled pre-formed tau aggregates.
ISSN:0304-4165
1872-8006
DOI:10.1016/j.bbagen.2018.04.001